Physician profile
Getnet Aberra
NPI 1801839170
$352.50
in general payments reported to CMS, 2019-2025
13 companies · $59.75 in 2025
The $59.75 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.02 · 2020: $24.42 · 2021: $31.83 · 2022: $56.88 · 2023: $101 · 2024: $34.99 · 2025: $59.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $67.82 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $50.49 | 2022-2023 | |
| Novo Nordisk INC | $50.17 | 2021-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.92 | 2019-2023 | Jardiance, Synjardy |
| Ardelyx, INC. | $34.99 | 2024 | Ibsrela |
| Dexcom, INC. | $18.42 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $17.69 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.63 | 2021 | |
| Glaxosmithkline, LLC. | $13.82 | 2025 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $13.55 | 2022 | |
| Genentech USA, INC. | $13.22 | 2019 | |
| Merck Sharp & Dohme LLC | $12.79 | 2019 | |
| Lemaitre Vascular, INC. | $7.99 | 2023 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Getnet Aberra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.